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ABSTRACT
Acute myeloid leukemia (AML) cells are highly dependent on glycolytic pathways 
to generate metabolic energy and support cell growth, hinting at specific, targetable 
vulnerabilities as potential novel targets for drug development. Elevated levels of 
NADPH, a central metabolic factor involved in redox reactions, are common in myeloid 
leukemia cells, but the significance or biochemical basis underlying this increase is 
unknown. Using a small molecule analog that efficiently inhibits NADPH-producing 
enzymes, we found that AML cells require NADPH homeostasis for cell growth. We also 
found that inhibiting NADPH production through knockdown of 6-phosphogluconate 
dehydrogenase (6PGD) within the pentose phosphate pathway was sufficient to 
reduce cell growth and lactate production, a measure of metabolic reprogramming. 
Further, inhibition of 6PGD activity reduced NADH levels and enzymatic activity of 
the oxidized NADH-dependent sirtuin-1. Targeting 6PGD and NADPH production 
was sufficient to block growth of AML cell lines resistant to the chemotherapeutics 
daunorubicin and cytarabine. Importantly, stromal cell-mediated resistance to 
targeted inhibition of oncogenic FLT3 kinase activity by quizartinib was circumvented 
by 6PGD knockdown. Overall, these data suggest that the dependency of AML cells on 
NADPH to permit increased glycolytic flux creates a potential vulnerability of possible 
therapeutic benefit, since much of the enhanced production of NADPH is dependent 
on the activity of a single enzyme, 6PGD.
INTRODUCTION
Acute myeloid leukemia (AML) is a genetically 
diverse cancer with a poor prognosis. Standard induction 
therapy with daunorubicin and cytarabine is plagued by 
the occurrence of drug resistance and does not lead to 
long-term remission in a large proportion of patients [1]. 
The only reliable treatment option that is an improvement 
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over induction therapy is allogeneic hematopoietic stem 
cell transplantation, but it is not suitable for all patients 
[2]. Sequencing of the genetic landscape in AML has 
defined the major mutational pathways. AML patient 
specimens contain on average 3 to 5 recurrent mutations 
out of 15 mutations per sample [3]. The hope is that this 
knowledge will lead to the development of personalized 
medicine that will drastically improve outcome in AML. 
Of interest here are activating mutations in tyrosine 
kinases, which have shown to be good therapeutic targets 
in other malignancies. The most common target in AML is 
represented by recurrent mutations in the receptor tyrosine 
kinase FLT3, which occur in about one third of all patients 
[4]. A number of FLT3 kinase inhibitors have been shown 
to induce partial and transient remissions in clinical trials of 
relapsed AML patients when administered as single agents 
[5]. Current results demonstrate significant survival benefit 
for mutant FLT3 positive AML patients treated with the 
newly FDA Breakthrough Therapy designated midostaurin 
[6–8]. This in particular points toward the importance of 
FLT3 as a therapeutic target, at least in patients harboring 
FLT3 mutations. However, as drug resistance develops in 
some newly diagnosed AML patients and the majority of 
AML patients with advanced disease, other disease-driving 
mutations may exist and additional therapeutic approaches 
for mutant FLT3-positive AML are needed [9, 10]. An 
additional issue with therapeutic approaches in myeloid 
malignancies is that bone marrow stromal cells appear 
to provide a protective environment that cancels growth 
inhibitory effects by oncogenic tyrosine kinase inhibitors, in 
particular with respect to early disease-initiating cells. Pre-
clinical models have been developed that capture some of 
these effects and they may help to identify novel approaches 
that can overwrite protective mechanisms [5, 11, 12].
Targeting reprogramming of glucose metabolism has 
emerged as an attractive and novel approach to developing 
new therapeutics in cancer treatment [13, 14]. The 
aberrant use of glucose and other carbon sources is part 
of a metabolic switch, leading to an increased glycolytic 
flux and elevated lactate production, even under aerobic 
conditions (Warburg effect) [15]. The pathways involved 
in glycolytic activities have been fairly well described in 
normal cells, but they may be intrinsically altered during 
oncogenic transformation. In myeloid malignancies, a 
hyper-active glucose metabolism is essential for increased 
mitochondrial electron transport chain activity [16, 17]. 
As a result, leukemic cells tend to produce an excess 
amount of reactive oxygen species during oxidative 
phosphorylation within the mitochondria. This oxidative 
stress is normally quenched by increased activity of the 
glutathione and thioredoxin scavenging systems to avoid 
toxicity [18]. NADPH plays a critical role as electron 
donor and scavenger of reactive oxygen in these reactions 
and its levels may be commonly elevated in leukemic cells 
[17]. However, the biochemical basis for this increase in 
AML is poorly understood.
6-phosphogluconate dehydrogenase (6PGD) and 
glucose-6-phosphate dehydrogenase (G6PD) within the 
pentose phosphate pathway are the major sources for 
NADPH in metabolically active cells [19]. Using cell-
based models of AML, we found that blocking NADPH 
production with the NADP+ analog β-nicotineamide 
adenine dinucleotide 3’-phosphate was sufficient to 
inhibit growth of cells resistant to the chemotherapeutics 
daunorubicin and cytarabine. We further defined the 
potential for targeted therapy through reducing aberrant 
NADPH levels by inhibition of 6PGD function. The 
results show that knockdown of 6PGD not only partially 
inhibits its metabolic activity but also significantly 
reduces cellular NADPH levels. Reduced NADPH levels 
further affected NADH homeostasis, thus indirectly 
reducing NADH-dependent sirtuin activity. Targeting 
6PGD cooperated in reducing cell growth in combination 
with daunorubicin and cytarabine treatment as well 
as in combination with inhibition of oncogenic FLT3 
kinase activity by quizartinib. Importantly, inhibiting 
6PGD activity or 6PGD-dependent mechanisms was 
sufficient to target drug-resistant cells, suggesting that 
6PGD represents a potential vulnerability that could aid 
chemotherapy.
RESULTS
Myeloid leukemia cells require elevated NADPH 
levels for cell growth
Hematopoietic cells transformed by oncogenic 
tyrosine kinases are not only characterized by an 
increased glycolytic flux and a change in the metabolic 
profile but also by an elevation in NADPH levels as part 
of the cellular system required to maintain redox balance, 
to facilitate anabolic reactions and to fuel additional 
biochemical reactions. Consistent with our previous 
findings that hematopoietic cells expressing tyrosine 
kinase oncogenes can increase NADPH levels [17], we 
found that AML and CML patient-derived cell lines 
transformed by FLT3-ITD (MOLM-13 and MV4.11), 
BCR-ABL (KU812) or JAK2V617F (HEL), showed 
significantly reduced NADPH levels (p<0.05) in response 
to their respective kinase inhibitors (Figure 1A, left). 
Variability in the overall range of NADPH level (17.2% 
- 70.1% reduction) in response to the tyrosine kinase 
inhibitors points towards somewhat different mechanisms 
of activation in metabolic pathways. In order to define 
the significance of altered NADPH levels, we used the 
NADPH analog, β-nicotineamide adenine dinucleotide 
3’-phosphate, as a chemical probe to target NADPH-
dependent reactions. This inhibitor efficiently blocked 
NADPH dependent biochemical reactions in vitro (not 
shown) as well as reduced NADPH levels in MOLM-13 
(33.8±3.8% of control), MV4.11 (23.8±1.6% of control), 
KU812 (43.7±12.6% of control) and HEL (39.3±1.0% 
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of control) in cell-based assays (Figure 1A, right). As 
a major challenge in AML therapy is the resistance to 
standard chemotherapy, we therefore generated cytarabine 
and daunorubicin resistant AML cell lines to test the 
effect of the NADPH analog on cell growth. Whereas 
parental MV4.11 cells were at least 100 times more 
sensitive to cytarabine (IC50 < 0.03 μM) than cytarabine-
resistant MV4.11 cells (IC50 = 3.22 μM), the difference 
between parental MV4.11 cells (IC50 = 20.01 μM) and 
daunorubicin-resistant MV4.11 cells (IC50 = 82.40 μM) 
was around four-fold (Figure 1B). In contrast, we observed 
considerably smaller differences in cell growth between 
parental MV4.11 cells (IC50 = 0.14 nM) and daunorubicin-
resistant MV4.11 cells (IC50 = 0.31 nM) and cytarabine-
resistant MV4.11 cells (IC50 = 0.74 nM) in response to 
the NADPH analog. The results demonstrate a crucial 
role for NADP/NADPH-dependent reactions in targeting 
cells resistant towards cytarabine and daunorubicine. 
Importantly, the efficacy of the NADPH analog was not 
limited to MV4.11 cells but was also found to reduce 
cell growth in KU812 (CML; IC50 = 0.37 mM), Molm13 
(AML; IC50 = 0.22 mM), MM1S (multiple myeloma; IC50 
= 0.17 mM) and RPMI-8226 (multiple myeloma; IC50 = 
0.82 mM) cells (Figure 1C). Specificity of this approach 
was determined in factor-independent, transformed BaF3 
cell lines, which allows for the comparison between 
normal (interleukin-3) signaling and oncogenic signaling 
(JAK2V617F, FLT3-ITD or TEL/JAK2) (Figure 1D). 
Treatment of these cells with interleukin-3 did not affect 
cell growth by itself in the absence of the NADPH 
analog. In contrast, the NADPH analog reduced cell 
growth and this effect could be rescued by interleukin-3 
treatment (p<0.005) in BaF3.EpoR.JAKV617F cells 
(-IL3: 19.7±1.4% of control versus +IL3: 54.2±4.4% of 
control), in BaF3.FLT3-ITD cells (-IL3: 31.9±1.8% of 
control versus +IL3: 86.3±5.6% of control) and in BaF3.
TEL/JAK2 cells (-IL3: 12.7±1.5% of control versus 
+IL3: 22.4±2.6% of control). Even though the NADPH 
analog functions as a chemical probe for these mechanistic 
studies, the results demonstrate a significant difference 
in the reliance on NADPH-dependent reactions between 
normal (IL3) and oncogenic signaling.
NADPH and NADH levels are dependent on 
functional 6PGD expression
The pentose phosphate pathway is thought to be 
the major source of reduced NADPH from its oxidized 
form through sequential oxidation of glucose-6-phosphate 
and 6-phosphogluconate by G6PD (glucose-6-phosphate 
dehydrogenase) and 6PGD (6-phosphogluconate 
dehydrogenase), respectively [19]. In order to determine 
the significance of this pathway and NADPH production 
for transformation, we specifically inhibited the second 
step of this reaction by targeted knockdown of 6PGD 
in MV4.11 cells. 6PGD expression was targeted with 
two different hairpins and reduction of 6PGD mRNA 
confirmed by semi-quantitative reverse transcription PCR 
(Figure 2A, left). Subclones of these cell lines with low 
6PGD expression determined by immunoblotting were 
used for subsequent experiments (Figure 2A, right). 
Further, reduced levels of 6PGD were also reflected in 
reduced enzyme activity in cells containing 6PGD hairpin 
A (60.8±0.3% of control) or hairpin B (36.4±0.8% of 
control) (Figure 2B, left). Importantly, even though we 
only found partial but significant inhibition of 6PGD 
enzyme activity and the hairpins specifically targeted 
the pentose phosphate pathway through 6PGD, we also 
observed significantly reduced lactate levels with 6PGD 
hairpin A (43.2±25.4% of control) or hairpin B (51.6±4.7% 
of control) (Figure 2B, right). The data suggest that 6PGD 
is an integral component of metabolic reprogramming in 
these cells.
As a result of suppressed 6PGD activity, we also 
detected reduced NADPH levels in cells containing 
6PGD hairpin A (61.0.8±12.7% of control) or hairpin B 
(57.7±4.9% of control) (Figure 2C, left). In addition to 
NADPH, we looked at levels of the related NADH in these 
cells as NADP is a product of the NAD kinase reaction 
[20]. Similar to NADPH, NADH levels were sensitive 
to inhibition of oncogenic FLT3 activity in MV4.11 cells 
by quizartinib (33.5.0.8±14.1% of control) (Figure 2C, 
middle). The changes in NADH levels were comparable 
to the reduction in cells containing 6PGD hairpin A 
(39.3±6.6% of control) or hairpin B (31.0±17.6% of 
control). To further define the biochemical consequences 
of altered NADH homeostasis, we measured sirtuin 
1 (SIRT1) activity, which is dependent on oxidized 
NADH. SIRT1 is of interest in AML since it thought to be 
involved in drug resistance mechanisms [21]. Similar to 
the metabolic changes associated with 6PGD knockdown, 
we also observed a reduction in SIRT1 activity with 6PGD 
hairpin A (51.8±0.3% of control) or hairpin B (53.2±2.5% 
of control) (Figure 2C, right).
SIRT1 is thought to be a key regulator of cellular 
metabolism and stress response genes, thus modulating 
a variety of cellular processes intrinsically related to 
transformation [22]. In order to define the role of SIRT1 
downstream of 6PGD, we used the SIRT1 inhibitors (S)-
35 and EX527 [23] to measure the effects on cell growth 
in parental MV4.11 cells as well as cells resistant to 
cytarabine and daunorubicin. Similar to the reduction of 
cell growth by the NADPH inhibitor (Figure 1B), both 
SIRT1 inhibitors reduced growth of MV4.11 cells in a 
dose-dependent manner (Figure 3A). The efficacy of both 
(S)-35 and EX527 in cytarabine-resistant MV4.11 cells 
(IC50 for (S)-35 = 12.8 μM; IC50 for EX527 = 36.5 μM) 
and daunorubicine-resistant MV4.11 cells (IC50 for (S)-35 
= 37.1 μM; IC50 for EX527 = 74.8 μM) remained similar 
compared to the parental MV4.11 cells (IC50 for (S)-35 = 
24.4 μM; IC50 for EX527 = 44.6 μM) and the results are 
similar to the efficacy in non-hematopoietic cells described 
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Figure 1: NADPH levels are required for increased growth. (A) Changes in NADPH levels were measured in cellular extracts 
of KU812 (BCR-ABL), HEL (JAK2.V617F), Molm13 (FLT3-ITD) and MV4.11 (FLT3-ITD) in response to inhibition (24 h) of their 
respective oncogenic tyrosine kinase activities, including imatinib (6 μM), ruxolitinib (400 nM), and quizartinib (0.8 nM) (left) or in 
response to the NADPH analog β-nicotineamide adenine dinucleotide 3’-phosphate (KU812 - 1.4 mM; HEL, Molm13, MV4.111 - 0.4 
mM) (right). *Significant differences (p<0.05; n=3) were observed between control and treated cells. Cell growth was measured (n=4) 
in (B) MV4.11 cells resistant to cytarabine (□) and daunorubicin (■) treated with either drug or the NADPH analog and compared to 
parental cells (♦) and in (C) KU812 (CML), Molm13 (AML), MM1S (multiple myeloma) and RPMI (lymphoma) treated with the NADPH 
analog, as indicated. (D) Untreated BaF3.EpoR.JAK2V617F (JAK2.V617F), BaF3.FLT3-ITD (FLT3-ITD) and BaF3.TEL/JAK2 cells 
were compared to cells treated with the NADPH analog, in the presence or absence of IL3. **Significant differences (p<0.005; n=4) were 
observed in response to IL3. Results were presented as mean ± SD.
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by others, such as the IC50 of (S)-35 for reducing migration 
in MDA-MB-231 (breast cancer) = 20 μM [24] or the 
IC50 of EX527 for reducing growth in MCF-7 (breast 
cancer) = 50 μM [25]. Since metabolic reprogramming 
is a common mechanism in transformed cells, we also 
looked to see whether SIRT1 inhibition was effective in 
other myeloid leukemia cells (Ku812, Molm13) as well 
as non-myeloid hematopoietic malignancies (MM1S, 
RPMI-8226). Similar to the above results, (S)-35 and 
EX527 inhibited growth in a dose-dependent manner at 
similar concentrations for (S)-35 (IC50 in Ku812 = 31.2 
μM, Molm13 = 41.4 μM, MM1S = 31.0 μM, RPMI-8226 
= 42.3 μM) and for EX527 (IC50 in Ku812 = 46.4 μM, 
Molm13 = 45.2 μM, MM1S = 79.4 μM, RPMI-8226 = 
45.5 μM) (Figure 3B). We further asked whether there 
are differences between oncogene-transformed and 
growth factor-dependent parental BaF3 cell lines with 
respect to inhibition with these inhibitors. Both S-35 and 
EX527 reduced cell growth in BaF3 cells (59.9±6.7% 
and 91.1±11.3% of control, respectively) and BaF3.EpoR 
(62.0±2.8% and 89.3±8.5% of control, respectively). 
However, growth was further reduced (p<0.05) by 
S-35 and EX527 in their FLT3-ITD (23.8±2.2% and 
68.8±5.3% of control, respectively) and EpoR.Jak2V617F 
(30.5±2.3% and 60.3±4.0% of control, respectively) 
counterparts (Figure 3C). The selective inhibition of AML 
Figure 2: 6PGD activity is required for optimal NADPH and NADH levels. MV4.11 cells expressing scrambled shRNA (Scr) 
were compared to 6PGD-targeting shRNA. (A) Changes in either 6PGD mRNA expression (construct A and B) or protein expression 
(construct A, MV4.11-clone A9 or construct B, MV4.11-clone B10) were determined. (B) Changes in 6PGD enzyme activity or in lactate 
levels as well as (C) changes in NADPH levels, NADH levels or SIRT-1 enzyme activity were measured in cellular extracts and compared 
to controls (CTRL). In some experiments, cells were treated with 0.8 nM quizartinib (Qu.) for 24h. *Significant differences (p<0.05; n=3) 
were observed between control and 6PGD knockdown cells. Results were presented as mean ± SD.
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Figure 3: Efficacy of sirtuin inhibitors in various cell lines. (A) Cell growth was measured (n=4) in MV4.11 cells resistant to 
cytarabine (□) and daunorubicin (■) that were treated with either the SIRT-1 inhibitor ‘compound (S)-35’ or the SIRT-1 inhibitor ‘EX527’ 
and compared to parental cells (♦). (B) Cell growth was measured (n=4) in KU812, Molm13, MM1S and RPMI-8226 treated with either 
compound (S)-35 (◊) orEX527 (■), as indicated. (C) BaF3 and BaF3.EpoR cells were compared to cells expressing either FLT3-ITD or 
JAK2V617F or (D) AML cells were compared to normal cells in response to 30 μM S-35 or 30 μM EX-527. Trend lines indicate the change 
in average. *Significant differences (p<0.05; n=3) were observed between control and transformed cells. Results were presented as mean 
± SD.
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transformed cells was also confirmed in primary AML 
patient specimen (n=8) versus normal controls (n=4) with 
a significant reduction in cell growth (p<0.05) for S-35 
(62.7% versus 82.2% of control) and EX-527 (40.8% 
versus 65.4% of control) (Figure 3D). These results do 
not exclude the possibility that other sirtuins or NADPH/
NADH-dependent reactions are involved in transformation 
of these cells but highlight the involvement of the 6PGD/
SIRT1 axis in cell growth.
Targeting 6PGD cooperates with standard 
therapy and circumvents stromal protection
Even though cytarabine and daunorubicin are 
established and effective chemotherapeutics, neither of 
them provides a reliable treatment option. There is an 
ongoing search for better treatment options in AML. One 
alternative could be to improve upon existing therapy 
and combine these drugs with novel targeted therapies 
to further reduce growth of leukemic cells. We therefore 
sought to establish whether targeting 6PGD cooperates 
with these chemotherapeutics using drug-sensitive 
parental and 6PGD knockdown cells. Consistent with 
the incomplete knockdown and partial reduction in 
metabolism, growth of MV4.11 cells containing hairpin A 
(39.4 ±3.0 to 40.7 ± 1.7% of control) and hairpin B (39.8 
±2.7 to 44.1 ± 4.1% of control) was reduced compared 
to untreated MV4.11 cells containing scrambled shRNA 
(not shown and Figure 4A and 4B). Both, cytarabine 
and daunorubicin further reduced cell growth in a dose-
dependent manner in all cells tested. We observed 
only marginal differences in growth between the two 
knockdown cell lines in response to either drug but found 
the 6PGD knockdown further reduced growth (Figure 4A 
and 4B). The data imply that 6PGD targeting does not 
interfere with the action of these chemotherapeutics and 
inhibiting this enzyme would cooperate with their effects 
on cell growth. Similar results were found with the FLT3 
inhibitor quizartinib, which selectively inhibits oncogenic 
FLT3-ITD tyrosine kinase activity in MV4.11 cells 
(Figure 4C). Oncogenic FLT3 kinase activity is involved 
in metabolic reprogramming of leukemic cells [17, 26], 
yet targeting 6PGD also did not cancel the dose-dependent 
inhibition of cell growth by quizartinib. The results hint 
at a unique mechanism that may cooperate with anti-
cancer drugs and improve the overall efficacy of targeted 
approaches.
Drug resistance is the main obstacle of successful 
leukemia treatment. In particular the stromal cell 
microenvironment is thought to protect early leukemic 
cells by providing stimuli that also support growth and 
viability of hematopoietic stem cells [11, 27]. We used an 
in vitro stromal cell model that has been well-characterized 
and includes conditioned medium from HS5 and HS27 
stromal cell lines. These cells are capable of producing a 
variety of cytokines that are sufficient to support growth 
in drug resistance models of AML [28–31]. Stromal 
cell-conditioned medium does not enhance cell growth 
in MV4.11 cells but has a somewhat suppressive effect 
(HS5 at 0.67 ± 0.09 fold change and HS27 at 0.77 ± 
0.04 fold change for MV4.11 cells; HS5 at 0.46 ± 0.03 
fold change and HS27 at 0.65 ± 0.11 fold change for 
MV4.11 with 6PGD knockdown) (Figure 4D), possibly 
due to suppressive cytokines, nutrient exhaustion in 
the conditioned medium and the fact that the dominant 
growth-stimulating pathways are already activated. In 
the presence of quizartinib, cell growth is significantly 
suppressed (see also Figure 4C) The cytoprotective 
effects of the conditioned medium partially overwrites 
this growth suppression and leads to a net increase in 
viable cells, when compared to cells treated with control 
medium. As expected, there were no differences in the 
absence of quizartinib. The fold increases in viable cells 
relative to control-treated cells were less pronounced at 
0.8 nM quizartinib (HS5 at 1.49 ± 0.09% fold change and 
HS27 at 1.34 ± 0.16 fold change) compared to a more 
potent concentration of 1.6 nM quizartinib (HS5 at 2.33 
± 0.52 fold change and HS27 at 1.81 ± 0.42 fold change) 
as a function of lower rescue potential relative to weaker 
growth suppression at lower drug concentrations. In 
contrast, the effect of stromal cell-conditioned medium 
was cancelled in MV4.11 with 6PGD knockdown and we 
did not observe significant increases between untreated 
cells (HS5 at 0.46 ± 0.03 fold change and HS27 at 0.65 ± 
0.11 fold change), 0.8 nM quizartinib-treated cells (HS5 
at 0.40 ± 0.02 fold change and HS27 at 0.70 ± 0.07 fold 
change) or 1.6 nM quizartinib-treated cells (HS5 at 0.66 
± 0.05 fold change and HS27 at 0.77 ± 0.11 fold change).
DISCUSSION
The goal of current metabolomics research in 
cancer cells is to find strategies to selectively target AML 
cells exhibiting increased glycolytic flux with a relative 
sparing of normal cells [14]. We have previously shown 
that tyrosine kinase oncogenes in myeloid leukemias 
lead to a specific, yet broad increase in metabolite 
levels [32]. In particular, glucose metabolic pathways 
can distinguish AML from normal hematopoietic cells. 
The challenge is to identify the metabolic switches 
that control metabolic reprogramming. Our data have 
defined changes in NADPH levels in leukemic cells and 
identified 6PGD as one major enzyme that is specifically 
involved in this process. The role of 6PGD in NADPH 
production in itself is not surprising as it is together with 
G6PD one of the two major NADPH producing enzymes 
in the pentose phosphate pathway [19]. One unexpected 
finding here is the fact that partial inhibition (36-61% of 
control) of 6PGD enzyme activity is sufficient to reduce 
NADPH levels (58-61% of control) and growth (39-44% 
of control) to a similar extent, suggesting that 6PGD acts 
as a key regulator and points at a vulnerability within 
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this pathway. Partial genetic deficiencies of this enzyme 
are largely tolerated by humans [33–35], suggesting 
that small molecule drugs that directly target 6PGD, or 
that lower pentose phosphate pathway activity, could 
provide therapeutic benefit in myeloid leukemias with 
minimal toxicity. In lung cancer models, functional 6PGD 
expression [36, 37] and acetylation [38] were associated 
with tumor growth. These data also hinted at a broader 
up-regulation of 6PGD activity in cancers, including 
in myeloid leukemias [38]. Thus, identifying potential 
metabolic switches in leukemic cells and validating these 
enzymes as potential therapeutic targets may also have 
implications for other cancers. However, considering 
the number of metabolic differences between normal 
and transformed cells and differences within the pool of 
patient specimen already found in our previous work [32], 
it is quite likely that metabolic dependencies may not be 
universal. For example, comparative proteome analysis 
found 6PGD to be specifically associated with AML 
subtype M2 but not M1 [39]. Whether this is also reflected 
in metabolic differences is unknown.
Our results provide an additional proof-of-concept 
for the approach of identifying and targeting metabolic 
switches and defining their role as a central mechanism 
in metabolic reprogramming and transformation. The 
results not only contribute to the understanding of 
metabolic networks and the interdependency of pathways 
therein, but also emphasize the potential of 6PGD and 
related molecules as targets to inhibit drug-resistant 
cell populations. As drug resistance is a major obstacle 
in AML, our results in particular with drug-resistant 
and drug-naïve models are of utmost clinical relevance. 
Mutant FLT3 has emerged as a convenient target in AML, 
but growth inhibition by selective inhibitors does not 
necessarily target the leukemic population that is protected 
by the stromal cell microenvironment. The protective 
mechanism appears to include at least in part stromal cell 
secreted cytokines that activate some of the very same 
pro-tumor pathways (i.e. phospho-STAT5) activated by 
oncogenic FLT3 [30].
Relative to normal hematopoietic progenitors, 
inhibition of 6PGD may not necessarily provide a wide 
Figure 4: 6PGD is required for increased growth. Cell growth was measured (n=4) in MV4.11 cells containing 6PGD-targeting 
shRNA construct A (■), construct B (▲) and parental cells (♦) that were treated with (A) cytarabine, (B) daunorubicin or (C) the FLT3 
inhibitor quirzatinib (Qu.), as indicated. (D) Cell growth was measured in a stromal cell model using either conditioned medium (CM) from 
HS5 or HS27 stromal cells. Fold changes in viable cells in response to conditioned medium were calculated relative to medium control-
treated cells and measured in MV4.11 cells expressing scrambled shRNA (control) or 6PGD-targeting shRNA (k.d.) treated with different 
concentrations of quirzatinib. *Significant differences (p<0.05) were observed between control and treated cells. Results were presented 
as mean ± SD.
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enough therapeutic window to eradicate those leukemic 
cells on its own but it may be suitable to prevent growth- 
promoting signals within this niche. Our cytarabine drug 
resistance model, where we achieve higher levels of 
resistance compared to the daunorubicin-resistant cells, 
also demonstrates high efficacy of 6PGD as compared 
with traditional therapy with only marginal differences in 
IC50 values observed. It would be interesting to determine 
the effect of selective 6PGD inhibitors within this pathway 
as they become available. Nevertheless, previous studies 
have pointed to a metabolic weakness in cancer stem cells, 
which may make them more susceptible to metabolic 
approaches [40, 41]. It is likely that targeting 6PGD or 
related metabolic switches may cooperate with many 
chemotherapeutics and enhances toxicity in leukemic stem 
cells that may lead to their eradication.
It is not entirely clear from our data how 6PGD 
inhibition mediates growth suppression, but changes 
in NADH and lactate levels suggest that remodeling of 
metabolic pathways and substrate availability are part 
of an oncogenic network. For example, we have shown 
that knockdown of 6PGD alters NADH homeostasis and 
correlated with NAD+-dependent SIRT1 activity. SIRT1 
is overexpressed in CD34+ AML [21], with a minimal role 
in normal hematopoietic cells [42] but involvement in 
metabolism, cell cycle control, metabolism, DNA repair 
and survival of cancer cells [22]. This is consistent with 
our data demonstrating reduced sensitivity towards sirtuin 
inhibitors in normal or growth-factor dependent models 
compared to AML or transformed cells. However, reduced 
NADH levels do not lead to concurrent reduced sirtuin 
activity [43]. SIRT1 can be regulated by a variety of 
mechanisms [44] and it would be interesting to sort out 
the complexity of metabolic changes caused by altered 
6PGD activity that may contribute to this change. SIRT1 
activity is of interest here since it has been implicated in 
the maintenance and drug resistance of FLT3-ITD-positive 
AML stem cells [21]. Indeed, our results are consistent 
with these findings and extend the efficacy of SIRT-
targeted approaches to daunorubicin- and cytarabine-
resistant cells. SIRT1 inhibition may also be an option in 
other hematologic malignancies that are plagued by drug 
resistance.
Similar to targeting 6PGD directly, the non-reactive 
small molecule NADPH analog, β-nicotineamide adenine 
dinucleotide 3’-phosphate, was effective in models of 
drug resistance and also inhibited growth of CML and 
multiple myeloma cancer cell lines. This approach may 
not be exclusive to inhibition of 6PGD and likely has 
some overlap with activities against other enzymes that 
can bind NADPH, even though we detected inhibitory 
activity of this compound against recombinant 6PGD 
(not shown). Despite the limitations of this approach, 
we found that factor-dependent growth stimulation was 
less sensitive to this inhibitor than oncogene-mediated 
growth, confirming increased dependency on NADPH-
driven pathways in transformed cells. Thus, the results 
highlight the potential of inhibitors that interfere with 
NADPH homeostasis. Targeting NADPH levels may also 
significantly increase the efficacy of chemotherapeutics in 
leukemic cells that act through oxidative stress-inducing 
mechanisms. As leukemic cells tend to produce an excess 
amount of reactive oxygen species during oxidative 
phosphorylation within the mitochondria [16, 17], 
oxidative stress is balanced by increased activity of the 
glutathione and thioredoxin scavenging systems to avoid 
toxicity. NADPH plays a central role as an electron donor 
within these reactions, and reducing its levels will likely 
result in higher sensitivity of cancer cells toward stress-
inducing events.
MATERIALS AND METHODS
Cell culture
Human cell lines KU812 (Ph+; CML), MOLM-
13 (FLT3ITD+; AML) and MV4.11 (FLT3-ITD; AML), 
MM1S (multiple myeloma), RPMI-8226 (multiple 
myeloma), HS-5 (bone marrow stroma), HS-27 (bone 
marrow stroma) were grown in RPMI 1640 (GIBCO, life 
technologies, Carlsbad, CA) containing 10% fetal bovine 
serum (FBS; GIBCO, life technologies) and medium for 
HEL cells (JAK2.V617F+; erythroleukemia) contained 
additional sodium pyruvate (1mM; Invitrogen, Grand 
Island, NY). Murine BaF3 cells transformed by FLT3-ITD, 
TEL-JAK2 and BaF3 cells expressing the erythropoietin 
receptor (BaF3.EpoR) and expressing JAK2V617F were 
maintained in RPMI 1640 containing 10% fetal bovine 
serum. Parental BaF3 and BaF3.EpoR cells were 
maintained in medium containing additional WEHI-
3B-conditioned medium as a source for interleukin-3 
(IL3). Cell lines were from ATCC and were either used 
within 6 months or submitted for cell line authentication 
and were authenticated within 6 months of manuscript 
preparation through cell line short tandem repeat (STR) 
profiling (DDC Medical, Fairfield, OH and Molecular 
Diagnostics Laboratory, Dana-Farber Cancer Institute). 
All cell lines tested matched ≥80% with lines listed in the 
ATCC or DSMZ Cell Line Bank STR. Peripheral blood 
mononuclear cells (PBMCs) from normal individuals and 
mononuclear cells from AML patients were isolated by 
density gradient centrifugation through Ficoll-Plaque Plus 
(Amersham Pharmacia Biotech AB, Uppsala, Sweden) at 
400g for 25 minutes, followed by two washes in PBS. 
Cells were then maintained in IMDM, supplemented with 
20% FBS. Primary cells were obtained through written 
consent under approval of the Dana-Farber Cancer 
Institute Institutional Review Board. In some experiments, 
cells were treated with kinase inhibitors, including 
imatinib (Gleevec, Novartis, Basel, Switzerland), 
ruxolitinib (Active Biochemicals, Hong Kong, China), 
and quizartinib (Haoyuan Chemexpress, Shanghai, 
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China), or SIRT-1 inhibitors, including compound (S)-
35 (Santa Cruz Biotech., Dallas, TX) and EX527 (Santa 
Cruz Biotech.) or treated with β-nicotinamide adenine 
dinucleotide 3’-phosphate (Sigma-Aldrich, St. Louis, 
MO), cytarabine (Santa Cruz Biotechn.) and daunorubicin 
(Santa Cruz Biotechn.). Drug resistant MV4.11 cells were 
generated by outgrowth of cell population after selection 
with cytarabine (300 nM) and daunorubicin (17.5 nM).
Cell growth
Cell growth was measured by trypan blue (Sigma-
Aldrich) exclusion or with the CellTiter 96 Aqueous One 
Solution Cell Proliferation Assay reagent (Promega, 
Madison, WI). The CellTiter-Glo Luminescent Cell 
Viability Assay Kit (Promega, USA) was used to measure 
growth in BaF3 cell lines and primary cells, according to 
the manufacturer's instructions.
Immunoblotting
Immunoblotting was performed as described 
previously using a standard chemiluminescence 
technique [45]. Rabbit monoclonal antibodies against 
6-phosphogluconate dehydrogenase (ab129199, Abcam, 
Cambridge, MA) and mouse monoclonal antibodies 
against ß-actin (12H8; Sigma-Aldrich) were used to 
document changes.
Measurement of NADPH and NADH levels
NADPH and NADH levels were measured using 
NADPH and NADH calorimetric quantification kits 
(Abcam) according to the manufacturer’s directions. 
Changes in levels were calculated relative to levels in 
extracts from untreated control cells.
SIRT1 enzyme activity
Relative changes in SIRT1 activity were measured 
using a fluorometric SIRT-1 Activity Assay Kit (Abcam) 
according to the manufacturer’s directions.
Measurement of lactate production
Lactate production was measured in the supernatant 
of 1x106 cells after incubation for 3h in serum-free medium 
using the Lactate Assay Fluorometric Kit (BioVision, 
Mountain View, CA).
6PGD enzyme activity assay
Cellular lysates were prepared in M-PER™ 
Mammalian Protein Extraction Reagent (Thermo 
Scientific, Waltham, MA) and 6PGD activities were 
determined by measuring the reduction of NADP+. 
Cell extracts were resuspended in a buffer containing 
94 mM glycylglycine (pH 7.4 at 37°C) and 1.7 mM 
6-phosphogluconate (Sigma). The reaction was started by 
the addition of 2.0 mM NADP+ (Sigma) and the increase 
in absorbance at 340 nm as a result of NADPH production 
was measured for 1 h. Changes in 6PGD activity were 
calculated relative to controls.
Semi-quantitative real-time PCR
6-PGD gene expression was measured by semi-
quantitative real-time PCR using specific primers 
(forward 5’-CGGATCATCCTCCTGGTG-3’; reverse 
5’-ATGATGTCACCAGTATCCAACAA-3’) and human 
60S acidic ribosomal phosphoprotein P0 (hRPLPO) 
control primers (forward 5′-GTGATGTGCAGCTG 
ATCAAGACT-3′; reverse 5’-GATGACCAGCCCAAAGG 
AGA-3’) to confirm efficient knockdown. Total RNA 
was extracted (RNeasy kit, Qiagen, Valencia, CA) 
to synthesize cDNA (Taqman Reverse Transcription 
Reagents, Applied Biosystems, Foster City, CA) for semi-
quantitative real-time PCR (Power SYBR green PCR 
master mix, Applied Biosystems) using a 7500 Real-Time 
PCR System (Applied Biosystems).
Targeted knockdown using lentiviral approaches
Knockdown of 6PGD was performed using two 
different lentiviral constructs (A and B; RNAi Screening 
Facility, Dana-Farber Cancer Institute) containing 
shRNA against 6PGD and compared to a scrambled 
control. Lentiviruses were generated by co-transfecting 
HEK293T cells with viral packaging vectors pMD2.G and 
pCMVΔ8.91 as well as shRNAs using the TransIT (Mirus, 
Madison, WI) reagent. KU812 cells were infected in the 
presence of polybrene (5μg/mL; Millipore, Temecula, 
CA) and selected for one week in medium containing 
puromycin (1μg/mL; Sigma).
Statistical analysis
For statistical comparison between test and 
control groups, the Student’s t-test or the Welch’s t-test 
(experiments involving stromal cell-conditioned medium 
and quizartinib only) were used. Changes were calculated 
as the percentage change relative to the average of the 
control. Error bars represent standard deviation (SD) of at 
least three independent experiments.
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